Impact of antituberculosis treatment on virological response to highly active antiretroviral therapy: Implications for resource-limited settings? [1]

Journal of Infectious Diseases

Volumn 194, Issue 10, 2006, Pages 1467-1468

  Lawn, Stephen D ^a,b   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NEVIRAPINE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUBERCULOSTATIC AGENT;

DISEASE ASSOCIATION; HEALTH CARE DELIVERY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LETTER; MORBIDITY; MORTALITY; PATIENT CARE; PRIORITY JOURNAL; SOUTH AFRICA; THAILAND; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; HIV; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; TUBERCULOSIS; VIRAL LOAD;

EID: 33750728452     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/508549     Document Type: Letter

References (10)

1. Breen RAM, Miller RF, Gorsuch T, et al. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J Infect Dis 2006; 193:1437-40 .
2. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009-21.
3. Lawn SD, Bekker L-G, Middelkoop K, Myer L, Wood R. Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis 2006; 42:1040-7.
4. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605-12.
5. World Health Organisation. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Executive summary. Available at: http://www .who.int/hiv/pub/prev_care/en/ARVGuidelines Revised2003.pdf. Accessed 15 April 2005.
6. Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001; 164:7-12.
7. Autar RS, Wit FW, Sankote I, et al. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther 2005; 10:937-43.
8. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS 2005; 19:1481-6.
9. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006; 20:131-2.
10. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005;5:361-73.